Evaluation System Leads to Incontinence Relief
By HospiMedica International staff writers Posted on 23 Oct 2014 |
An innovative evaluation system for incontinence therapy offers a more discreet and unobtrusive experience for patients during the evaluation period.
The Medtronic Verify Evaluation System is used temporarily to determine if bladder or bowel control therapies to be delivered by the Medtronic InterStim System, may provide long-term relief for patients suffering from chronic symptoms of overactive bladder, non-obstructive urinary retention, or bowel incontinence, who had failed or were not candidates for more conservative therapies. The system consists of a small, external neurostimulator that is concealed securely in a soft belt worn at the waist under clothing, and a mobile phone-sized wireless controller with a touch-screen for easy stimulation adjustments.
The system is used following a minimally invasive outpatient procedure to place the lead, and includes a usage log that allows physicians to effectively manage patient evaluations by reviewing the operation of the system and matching it against a patient's diary of daily bladder or bowel episodes. Results of the therapy vary, and not every patient's response is the same; in addition to risks related to any medical procedure, complications can include pain, infection, sensation of electrical shock, device problems, undesirable change in voiding function, and lead migration.
Both the Verify System and the long-term InterStim System provide mild electrical stimulation to the sacral nerves, a therapy thought to help normalize communication between the bladder (or bowel) and the brain. The implantable components of the system consist of a neurostimulator and a lead that are implanted under the skin following a successful trial stimulation period with the Verify Evaluation System. The Medtronic Verify Evaluation and InterStim systems are products of Medtronic (Minneapolis, MN, USA).
“More than 150,000 patients worldwide have received Medtronic bladder control or bowel control therapies, and we are excited to bring the latest advancement in evaluation technology to physicians and patients,” said Linnea Burman, vice president and general manager of gastro/urology therapies at Medtronic. “The Verify System reinforces Medtronic's commitment to innovative solutions for the treatment of overactive bladder, urinary retention and bowel incontinence.”
“Mild stimulation of the sacral nerves can have a significant impact on patients suffering from overactive bladder, urinary retention, or bowel control issues. The trial stimulation period allows them to try the therapy before having a neurostimulator implanted,” said Ken Peters, MD, chief of urology at Beaumont Hospital (Royal Oak, MI, USA). “This new trial system provides me with vital information so I can determine if the long-term therapy is right for individual patients.”
Related Links:
Medtronic
The Medtronic Verify Evaluation System is used temporarily to determine if bladder or bowel control therapies to be delivered by the Medtronic InterStim System, may provide long-term relief for patients suffering from chronic symptoms of overactive bladder, non-obstructive urinary retention, or bowel incontinence, who had failed or were not candidates for more conservative therapies. The system consists of a small, external neurostimulator that is concealed securely in a soft belt worn at the waist under clothing, and a mobile phone-sized wireless controller with a touch-screen for easy stimulation adjustments.
The system is used following a minimally invasive outpatient procedure to place the lead, and includes a usage log that allows physicians to effectively manage patient evaluations by reviewing the operation of the system and matching it against a patient's diary of daily bladder or bowel episodes. Results of the therapy vary, and not every patient's response is the same; in addition to risks related to any medical procedure, complications can include pain, infection, sensation of electrical shock, device problems, undesirable change in voiding function, and lead migration.
Both the Verify System and the long-term InterStim System provide mild electrical stimulation to the sacral nerves, a therapy thought to help normalize communication between the bladder (or bowel) and the brain. The implantable components of the system consist of a neurostimulator and a lead that are implanted under the skin following a successful trial stimulation period with the Verify Evaluation System. The Medtronic Verify Evaluation and InterStim systems are products of Medtronic (Minneapolis, MN, USA).
“More than 150,000 patients worldwide have received Medtronic bladder control or bowel control therapies, and we are excited to bring the latest advancement in evaluation technology to physicians and patients,” said Linnea Burman, vice president and general manager of gastro/urology therapies at Medtronic. “The Verify System reinforces Medtronic's commitment to innovative solutions for the treatment of overactive bladder, urinary retention and bowel incontinence.”
“Mild stimulation of the sacral nerves can have a significant impact on patients suffering from overactive bladder, urinary retention, or bowel control issues. The trial stimulation period allows them to try the therapy before having a neurostimulator implanted,” said Ken Peters, MD, chief of urology at Beaumont Hospital (Royal Oak, MI, USA). “This new trial system provides me with vital information so I can determine if the long-term therapy is right for individual patients.”
Related Links:
Medtronic
Read the full article by registering today, it's FREE!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
- Free digital version edition of HospiMedica International sent by email on regular basis
- Free print version of HospiMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of HospiMedica International in digital format
- Free HospiMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Critical Care News
- AI to Improved Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia